Frier Levitt attorney Guilherme Ferrari presents “Custom Meds, Custom Risks: Compounding Litigation and Enforcement” at the Food and Drug Law Institute’s (FDLI) Enforcement, Litigation & Compliance Conference on Friday, December 5, 2025, from 11:35 AM – 12:35 PM ET in Washington, DC.
This panel will examine the dynamic and high-stakes landscape of pharmaceutical compounding enforcement, litigation, and regulatory compliance, including:
- Market dynamics and regulatory considerations now that the GLP-1 drug shortage has ended
- Efforts by branded manufacturers to restrict compounding of commercially available GLP-1 products, including private litigation under trademark, unfair competition, and other legal theories
- Enforcement priorities by regulators relating to 503A pharmacies, 503B outsourcing facilities, medspas/weight-loss clinics, and telehealth providers
- Regulatory compliance and marketing considerations associated with compounded GLP-1 products
The FDLI Conference brings together regulators, industry leaders, and attorneys shaping policy and enforcement strategy across FDA-regulated sectors.
How Frier Levitt Helps:
Frier Levitt attorneys advise on FDA regulatory compliance, marketing practices, licensure, and litigation strategy helping clients navigate enforcement scrutiny while staying positioned for growth. Connect with our attorneys.
